A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote
the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is
to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with
previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are
chemotherapy ineligible or who refuse chemotherapy.